Aberrant activation of EGFR and HER3 receptors, together with overexpression of multiple EGFR ligands, has also been observed in sorafenib-resistant HCC, providing an additional mechanism for drug evasion [140]. Here, EGFR is linked to hepatocellular carcinoma.